TI
CLVS

tru Independence’s Clovis Oncology, Inc. CLVS Stock Holding History

tru Independence’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,095
Closed -$34 – 911
2020
Q2 		$34 Buy
5,095
+600
+13% +$4.54K ﹤0.01% 432
2020
Q1 		$4.5K Hold
4,495
– – 0.73% 29
2019
Q4 		$29K Buy
+4,495
New +$32.7K ﹤0.01% 436

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

tru Independence's CLVS Position: Q3 2020 in Review

tru Independence sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 5,095 shares — an estimated $34 sold.

tru Independence first reported a position in CLVS in Q4 2019 and held it in 3 quarters. The position peaked at $29K in Q4 2019. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

  • tru Independence reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 5,095 Clovis Oncology, Inc. shares in Q3 2020, an estimated $34.
  • tru Independence first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 3 quarters.
  • tru Independence's Clovis Oncology, Inc. position peaked at $29K in Q4 2019.
  • 169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.